J&J MedTech exits DePuy Synthes spine portfolio

Johnson & Johnson MedTech will officially exit the DePuy Synthes Spine portfolio in Australia tomorrow, November 30, as part of its broader strategy to streamline operations. This decision, described as being made “after careful consideration,” was first announced on July 24.

Effective December 1, Evolution Surgical, an innovative Australian MedTech company, will take over as the exclusive point of contact for DePuy Synthes Spine removal sets. Evolution Surgical is known for its end-to-end operations spanning design, manufacturing, and distribution.

“Evolution Surgical will take possession of existing DePuy Synthes instruments to facilitate DePuy Synthes removal and revision requirements.

“Where operationally feasible, Evolution Surgical will provide specific DePuy Synthes instrument removal sets, with set screws available for growth constructs, where paediatric patients have a long-term surgical care plan requiring construct adjustments over time,” stated Andrew Giles, Chief Operating Officer of DePuy Synthes Australia, and Jack Lancaster, CEO of Evolution Surgical, in a joint letter to customers.

The announcement aligns with Johnson & Johnson’s broader initiative, unveiled last year, to exit “less profitable” markets and product lines within its orthopaedics division by the end of 2025.

“We are focused on having the right portfolio. We have a very strong team in the field, and we have a plan to be able to continue to improve our margins in orthopaedics,” said Johnson & Johnson CEO Joaquin Duato.

The transition marks a significant milestone for Evolution Surgical, which recently secured an investment from Quadrant Private Equity through its $530 million Growth Fund 2 in August. The private equity firm will partner with CEO Jack Lancaster and the Evolution Surgical management team to drive future growth.

Evolution Surgical’s portfolio includes advanced spinal implants and biologics designed to treat spinal tumours, deformities, trauma, and degenerative disc disease

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.